1 Considerations in Medication Assisted Treatment of Opiate Dependence AOAAM OMED Education Program Sunday, October 7, 2012 Stephen A. Wyatt, D.O. Addiction Psychiatrist Middlesex Hospital Middletown, Connecticut
2 Objectives Review the development, science and prescribing policies of the currently available medications for the treatment of opiate dependence. Understand the factors important in the decision of which treatment would be indicated. Understand the factors associated with the initiation of a treatment for opiate dependence.
3 Current Treatments Medically assisted withdrawal and abstinence. Methadone maintenance Naltrexone: oral and injectable Buprenorphine/naloxone
4 Fatal Poisonings in France - Decreases with Availability of Opiate Treatment Source:Carrieri PM, 2006, Clin Infect Dis, 43: S , data from Emmanueli, et al.
5 Historical Review The 1914 Harrison was a commerce act restricting the sales of narcotics, it excluded physician treating patients In 1919 when the Harrison Act was upheld by the Supreme Court it excluded the treatment of opiate dependence: not considered a disease. No longer was it legal for physicians to prescribe opiates maintaining opiate dependence or for the treatment of the disease. Medically assisted withdrawal of opiates and abstinence was the only legal treatment. The historical records identify the relapsing nature of this disease. Hunt and Odoroff 1962, Duvall et al. 1963
6 Historical Review As the death rate of heroin injection patients continued to rise in the late 50 s and early 60 s, with a concurrent rise in associated crime, there was growing support for the establishment of opiate maintenance programs. There was an increase in Federal funding for research into treating these patients. In 1962 Vincent Dole, MD received a grant to study the feasibility of opiate maintenance treatment. In1964 Marie Nyswander, MD, psychiatrist with experience in treating addicted patients joined the research team. Methadone was eventually selected as the most efficacious opiate for maintenance treatment.
7 Historical Review The Comprehensive Drug Abuse Prevention and Control Act of 1970 was a Nixon initiative in the evolution of the war on drugs. However, included was a Dept. of Health, Education, and Welfare authorization to improve drug prevention and treatment. This included, under the direction of Jerome Jaffe, MD a federal effort to widen the availability of opiate maintenance programs.
8 Historical Review The next approved medication for Opiate dependence was naltrexone approved in As an opiate antagonist it blocks the opiate receptor significantly changing the patient response to the administration of an opiate. The lack of compliance and less reduction in craving are thought to be the prominent problems associated with poor efficacy of the oral product. A sustained release form was determined to have an adequate safety profile and to be effective by the FDA in 2010.
9 Historical Review With the establishment of DATA 2000 another treatment option was made available. This act of congress established that any class III, IV, V controlled substance with FDA approval for opiate dependence treatment could be prescribed by a qualified physician. This opened the door to buprenorphine. Resulting in availability of office based opiate treatment with an agonist medication. This further broadened the available of maintenance treatment.
10 Medication Assisted Treatment of Opiate Dependence METHADONE
11 Neurobiology: Methadone blocks the euphoric and sedating effects of other opiates; reduces the craving for other opiates relieves symptoms associated with withdrawal from opiates; does not cause euphoria or intoxication itself (with stable dosing), thus allowing a person to work and participate near normal in society; Has a long half life and is excreted slowly allowing for once a day dosing. CDC 2002
12 Methadone Treatment Methadone maintenance treatment, a program in which addicted individuals receive daily doses of methadone. Multi-component treatment program Abstinence of other drugs of abuse including alcohol Resocialization Sober supports Vocational training Coordination of healthcare HIV Hepititis C Pregnancy
13 Methadone Treatment Identified benefits include: reduced or stopped use of injection drugs; Reduced risk of acquiring or transmitting diseases such as HIV, hepatitis B or C, bacterial infections, endocarditis, soft tissue infections, thrombophlebitis, tuberculosis, and STDs; possible reduction in sexual risk taking reduced risk of overdose reduced mortality death rate of opiatedependent individuals in MMT is 30 percent that of those not in MMT; Improved Social Status reduced criminal activity; improved family stability improved employment potential; improved pregnancy outcomes. CDC 2002
14 Methadone Treatment Drawbacks Physical dependence, possibly strengthening neurobiologicaladaptation to opiate dependence. Initial daily administration at a licensed methadone treatment center Early mild to moderate opiate like effects; e.g. sedation, reduction in cognitive awareness Long term maintenance effects on hormonal adaptations; reduction in testosterone, menstruation, calcium metabolism Drug/Drug interactions Neonatal abstinence syndrome
15 Methadone Formulation Methadone for Pain or Addiction Methadone for outpatient pain treatment is in tablet form. 410,000 patients in third quarter of 2006 Methadone used in managing opioid dependence is usually liquid or wafer 260,000 patients in March, 2006 SAMHSA, N-SSATS 2007 Report
16 Percent of methadone Mentions Methadone Formulations reported RADARS System (Rocky Mountain Poison and Drug Center) Drug Diversion Opioid Treatment Program
17 Medication Assisted Treatment of Opiate Dependence NALTREXONE
18 Neurobiology: Naltrexone Naltrexone, a opiate antagonist. Attaches to the opiate receptor without activation. PET studies that a single 50 mg dose of naltrexone in a naive subject results in a 90% blockade of mu receptors at 24 hours. At 48 hours it s about 72%, and even at 96 hours some blockade is still present. No physical dependence Possible reduction in opiate craving through a combination of; blockade of the opiate receptor effecting endorphin activation and dopamine activation of the nucleus accumbens or pleasure center in the brain. Total opiate blockade reducing initial consideration of opiate use.
19 Naltrexone: Treatment Naltrexone has great potential as a therapeutic drug in assisting patients opiate treatment, Oral However the oral administration failed because primarily due to poor compliance. Extended Release (XR) Injectable has antagonist effects that last many weeks. the XR-NTX formulation currently available results in blood levels of 1-2 nanograms per milliliter (ng/ml) can provide adequate blockade for four to five weeks. compliance, remains a problem but is less problematic
20 Naltrexone Oral vs. Injection
21 Naltrexone Treatment Drawbacks Patients needs to have completed the withdrawal process prior to being started on naltrexone, Otherwise precipitated withdrawal will occur. following the injection formulation it is likely to be more intense on day 2 than day 1 May elevate liver transaminases Patients cannot be on opiate pain medication. If injected may have injection site inflammation (particularly obese patients)
22 Naltrexone Adverse effects If reinitiating opiates patient may be at increased risk due to loss of tolerance and possible upregulation. Some evidence of up-regulation of receptors in patients on naltrexone, possible increased risk of overdose deaths. At this point there is only evidence of this in rats. One study in humans was negative but this remains a concern. Vitally important to tell patients who have stopped taking naltrexone that if they do go back to using heroin, starting with anything more than a very small dose might result in death.
23 Medication Assisted Treatment of Opiate Dependence BUPRENORPHINE
24 Neurobiology: Buprenorphine Partial opiate agonist High affinity Slow dissociation Displaces other opiates including heroin Improved safety profile due to reduction in potential respiratory depression
25 Buprenorphine Treatment Approved for office based treatment Allows for normalization of treatment in the primary care or behavioral health care practices. Allows for wider availability of agonist treatment Reduces potential for overdose Once a day administration Minimal drug interaction Relative blocking of other opiates Significant reduction in craving Improved reentry into normal socialization
26 Buprenorphine Treatment Drawbacks Physical dependence, possible strengthening of the opiate dependence. Diversion for sustained opiate dependence and non-dependent abuse May reduces the drive to put in place relapse prevention behaviors due to the pharmacologic reduction in the drive to use other opiates. There is evidence of both hormonal adaptation and neonatal abstinence syndrome though less than that seen in the Methadone treated patient.
27 Medication Assisted Treatment of Opiate Dependence TREATMENT SELECTION
28 Treatment Selection Logistical considerations Access to a methadone treatment center has been a major limitation to this form of treatment Buprenorphine has limited availability due to limited access to a waivered physician, though private office availability has improved treatment access in rural areas in particular. Physician access to assistance with drug counseling Need for detoxification of opiates prior to the administration of naltrexone.
29 Treatment Selection There is significant overlap in the indications of one form of therapy over another. Patients may have a strong bias to one form of treatment over another. Honoring this may improve compliance and effectiveness. Physician knowledge and level of comfort will also be a consideration.
30 Treatment Selection Patients co-occurring medical or psychiatric problems should be considered. Poly substance abuse may need the daily oversight of MMT Mental health problems - availability of buprenorphine in medical/behavioral health specialty clinics Pregnancy - The opportunity for the patient to be treated in an established methadone maintenance pregnancy program should be a strongly considered. However, buprenorphine is gaining greater evidence of reducing both days of NAS and morphine dose following delivery.
31 Treatment Selection Methadone Access to care sometimes easier than others and sometimes not Patient in need of greater supervision Greater concerns of diversion. Limited social supports available Polysubstance abuse or dependence Possibly those with higher daily dose of opiate use prior to treatment however this is now in dispute. Concurrent chronic pain
32 Treatment Selection Naltrexone Patient currently abstinent with history of frequent relapse, opiate craving Recently incarcerated Recently detoxified from opiate maintenance treatment Not anticipating surgical treatment or pain requiring opiate treatment. Physician not waivered to use schedule III drug for office based treatment. Patient with evidence of being moderately compliant with treatment. The injectable form can be coupled to strong contingencies improving compliance and outcomes.
33 Treatment Selection Buprenorphine Access to waivered physician Access to relapse prevention treatment Possible lower level of opiate use though this is in dispute. Opportunity for coordination with other services both medical and psychiatric. The evidence of a reduction in drug-drug interaction with buprenorphine over methadone should be considered in the HIV pos. population. Moderate level of social supports available. Concurrent chronic pain
34 Treatment Selection Cost Comparison of medications vs. no medication of costs for medications, inpatient, outpatient, and pharmacy costs, 29% lower for patients who received a medication for opioid dependence versus patients treated without medication. Injectable sustained release naltrexone had fewer opioid-related and non opioid-related hospitalizations than patients receiving oral medications. Total healthcare costs were not significantly different between oral or injectable naltrexone and buprenorphine, and were 49% lower than those for methadone. This in part was a reflection on the increase co-morbidity seen in the Methadone population. Baser, AJ of Managed Care, 2011
35 Medically Assisted Opiate Treatment Abstinence remains an option particularly in the young low level dependent patient. However: There is strong evidence of improved outcomes with medication assisted treatment Patients should be made aware of their options Treatment providers should be aware of these medications to better educate patients and make appropriate treatment recommendations.
36 Conclusion There are yet clear answers to what is the best opiate treatment for a specific patient. In the end it is between the doctor and patient to determine the best fit.
Considerations in Medication Assisted Treatment of Opiate Dependence Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Disclosures Speaker Panels- None Grant recipient - SAMHSA
Medication Assisted Treatment for Opioid Addiction Tanya Hiser, MS, LPC Premier Care of Wisconsin, LLC October 21, 2015 How Did We Get Here? Civil War veterans and women 19th Century physicians cautious
Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone ) Elinore F. McCance-Katz, M.D., Ph.D. Professor and Chair, Addiction Psychiatry Virginia Commonwealth University Neurobiology of Opiate
Neurobiology and Treatment of Opioid Dependence Nebraska MAT Training September 29, 2011 Top 5 primary illegal drugs for persons age 18 29 entering treatment, % 30 25 20 15 10 Heroin or Prescription Opioids
Treatment of opioid use disorders Gerardo Gonzalez, MD Associate Professor of Psychiatry Director, Division of Addiction Psychiatry Disclosures I have no financial conflicts to disclose I will review evidence
Substitution Therapy for Opioid Dependence The Role of Suboxone Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015 Objectives Recognize the options available in treating opioid
Medication Assisted Therapy and Pregnancy: An Introduction Deborah A. Orr, Ph.D. The Center For Drug Free Living Adapted from the NIDA Blending Initiative Curriculum Presentation Objectives Define opioids
MEDICATION ASSISTED TREATMENT (MAT) STATISTICS: ALCOHOL AND OPIOID USE Last year 33 Iowans died from opioid overdose deaths; an additional 19 individuals died of a heroin overdose. The number of drug overdose
Beyond SBIRT: Integrating Addiction Medicine into Primary Care Community Clinic Association of Los Angeles County 14 th Annual Health Care Symposium March 6, 2015 Keith Heinzerling MD, Karen Lamp MD; Allison
Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently asked questions What is Naltrexone? Naltrexone is a prescription drug that completely blocks the effects of all opioid drugs
This is a fact in the treatment of alcohol and drug abuse: Patients who do well in treatment do well in any treatment and patients who do badly in treatment do badly in any treatment. One example: Chapman
MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION Sidarth Wakhlu,M.D. Addiction Team Leader North Texas VA Health Care System Addiction Psychiatry Fellowship Director Associate Professor Of Psychiatry
Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently Asked Questions What is Naltrexone? Naltrexone is a prescription drug that effectively blocks the effects of heroin, alcohol,
Using Drugs to Treat Drug Addiction How it works and why it makes sense Jeff Baxter, MD University of Massachusetts Medical School May 17, 2011 Objectives Biological basis of addiction Is addiction a chronic
Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings All-Ohio Conference 3/27/2015 Christina M. Delos Reyes, MD Medical Consultant,
Ohio Legislative Service Commission Bill Analysis Brian D. Malachowsky H.B. 378 130th General Assembly () Reps. Smith and Sprague BILL SUMMARY Prohibits a physician from prescribing or personally furnishing
Frequently Asked Questions (FAQ s): Medication-Assisted Treatment for Opiate Addiction March 3, 2008 By: David Rinaldo, Ph.D., Managing Partner, The Avisa Group In this FAQ What medications are currently
Clinical Practice Approval Form Clinical Practice Title: Acute use of Buprenorphine for the Treatment of Opioid Dependence and Detoxification Type of Review: New Clinical Practice Revisions of Existing
Heroin Introduction Heroin is a powerful drug that affects the brain. People who use it can form a strong addiction. Addiction is when a drug user can t stop taking a drug, even when he or she wants to.
Medication is not a part of treatment. Medication can be an effective part of treatment. Medication is used in the treatment of many diseases, including addiction. Medical decisions must be made by trained
Ever wish you could... Quit using heroin? Protect yourself from HIV infection? Get healthier? Good News: Medical treatments called opioid (oh-pee-oyd) maintenance can help you! Injecting heroin puts you
Medication treatments for opioid use disorders Summary for counties JUDITH MARTIN, Medical Director of Substance Use Services, San Francisco Department of Public Health Brief history of Methadone and Buprenorphine
Joel Millard, DSW, LCSW Dave Felt, LCSW 1. Provide an overview of the effectiveness of medication assisted treatment, to include a discussion of the different types of medications and how they are used
BULLETIN INTELLIGENCE Product No. 2004-L0424-013 SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E NDIC Within the past 2 years buprenorphine a Schedule III drug has been made available for use
M00K02 Alcohol and Drug Abuse Administration Department of Health and Mental Hygiene The Use of Non-Opioid Pharmacotherapies for the Treatment of Alcohol Dependence Introduction The 2011 Joint Chairmen
MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION Mark Fisher Program Administrator State Opioid Treatment Adminstrator Kentucky Division of Behavioral Health OBJECTIVES Learn about types of opioids and
Heroin Heroin is a synthetic opiate drug that is highly addictive. It is made from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears
Office-based Treatment of Opioid Dependence with Buprenorphine David A. Fiellin, M.D Professor of Medicine, Investigative Medicine and Public Health Yale University School of Medicine Dr. Fiellin s Disclosures
Applicant Webinar for BJA s Drug Court Discretionary Grant Solicitation Cynthia Caporizzo, Senior Criminal Justice Advisor, Office of National Drug Control Policy (ONDCP) - Review of the administration
Medication Assisted Treatment of Substance Use Disorders Michael Ballue, CADC II, BSBA Geoff Kane, MD, MPH 1 Addiction: The Bare Essentials 2 Addiction The Person: Loss of Control The Observer: Persistent
Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call 1-800-662-HELP(4357)
Medications for Alcohol and Drug Dependence Treatment Robert P. Schwartz, M.D. Medical Director Rschwartz@friendsresearch.org Friends Research Institute Medications for Alcohol Dependence Treatment Disulfiram
TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION The Tennessee Board of Medical Examiners has reviewed the Model Policy Guidelines for Opioid Addiction Treatment
Drug Court EPIDEMIC In the 10 years (1997 2007) the per capita retail purchases of Methadone, Hydrocodone and Oxycodone in the United States increased 13-fold, 4-fold and 9-fold, respectively. 4.6 % OF
Heroin Heroin is an opiate drug that is synthesized from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears as a white or brown
Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Marvin D. Seppala, MD Chief Medical Officer Hazelden Betty Ford Foundation This product is supported by
Dependence and Addiction Marek C. Chawarski, Ph.D. Yale University David Metzger, Ph.D. University of Pennsylvania Overview Heroin and other opiates The disease of heroin addiction or dependence Effective
Page 43 by 42 CFR part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. Information for Pharmacists SUBOXONE (buprenorphine HCl/naloxone HCl
Optum 1 By United Behavioral Health U.S. Behavioral Health Plan, California Doing Business as OptumHealth Behavioral Solutions of California ( OHBS-CA ) 2015 Level of Care Guidelines Opioid Treatment Services,
Prior Authorization Guideline Guideline: CSD - Suboxone Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Analgesics and Antipyretics (Opiate Partial Agonists) Client: County of San
visited on Page 1 of 5 LEARN MORE (HTTP://WWW.NAMI.ORG/LEARN-MORE) FIND SUPPORT (HTTP://WWW.NAMI.ORG/FIND-SUPPORT) GET INVOLVED (HTTP://WWW.NAMI.ORG/GET-INVOLVED) DONATE (HTTPS://NAMI360.NAMI.ORG/EWEB/DYNAMICPAGE.ASPX?
Official reprint from UpToDate www.uptodate.com 2015 UpToDate Pharmacotherapy for opioid use disorder Author Eric Strain, MD Section Editor Andrew J Saxon, MD Deputy Editor Richard Hermann, MD All topics
Use of Vivitrol for Alcohol and Opioid Addiction Ken Bachrach, Ph.D. Clinical Director, Tarzana Treatment Centers, Inc. email@example.com What is Vivitrol? An injectable from of naltrexone, which
Opioid Addiction and Methadone: Myths and Misconceptions Nicole Nakatsu WRHA Practice Development Pharmacist Learning Objectives By the end of this presentation you should be able to: Understand how opioids
BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) Based on the Work of Dr. Thomas Freese of the Pacific Southwest ATTC Drug Addiction Treatment Act of 2000 (DATA 2000) Developed by Mountain West
Outpatient Treatment of Opiate Dependence with Sublingual Buprenorphine/Naloxone versus Methadone Maintenance: a Randomized Trial of Alternative Treatments in Real Life Settings Joanna L. Starrels A. Study
Medication-Assisted Addiction Treatment Molly Carney, Ph.D., M.B.A. Executive Director Evergreen Treatment Services Seattle, WA What is MAT? MAT is the use of medications, in combination with counseling
Treatment for Addiction in the Community Reduces Drug Use, Crime and Recidivism Richard A. Rawson, Ph.D, Professor Semel Institute for Neuroscience and Human Behavior David Geffen School of Medicine University
Update and Review of Medication Assisted Treatments for Opiate and Alcohol Use Disorders Richard N. Whitney, MD Medical Director Addiction Services Shepherd Hill Newark, Ohio Medication Assisted Treatment
Heroin Heroin is an opiate drug that is synthesized from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears as a white or brown
DrugFacts: Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please
The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office Adopted April 2013 for Consideration by State Medical Boards 2002 FSMB Model Guidelines
Category: Heroin Title: Methadone Maintenance vs 180-Day psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial Authors: Karen L. Sees, DO, Kevin L. Delucchi,
Buprenorphine Clinical Guide Quick Guide For Physicians Based on TIP 40 Clinical Guidelines for the Use of Buprenorphine in the Treatment Clinical Guidelines for the Use of Buprenorphine in the Treatment
Buprenorphine/Naloxone Maintenance Treatment for Opioid Dependence Information for Family Members Family members of patients who have been prescribed buprenorphine/naloxone for treatment of opioid addiction
Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary Which of the following is an
A GUIDE FOR USERS UNaltrexone abstinence not using a particular drug; being drug-free. opioid antagonist a drug which blocks the effects of opioid drugs. dependence the drug has become central to a person
Page: 1 of 7 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
Governor s Cabinet Opiate Action Team Promoting Wellness and Recovery John R. Kasich, Governor Tracy J. Plouck, Director Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio November 14,
Buprenorphine: what is it & why use it? Dr Nicholas Lintzeris, MBBS, PhD, FAChAM Locum Consultant, Oaks Resource Centre, SLAM National Addiction Centre, Institute of Psychiatry Overview of presentation
Non medical use of prescription medicines existing WHO advice Nicolas Clark Management of Substance Abuse Team WHO, Geneva Vienna, June 2010 firstname.lastname@example.org Medical and Pharmaceutical role Recommendations
Presentation to Senate Health and Human Services Committee: Prescription Drug Abuse in Texas David Lakey, MD Commissioner, Department of State Health Services Lauren Lacefield Lewis Assistant Commissioner,
ISSUE DATE September 4, 2015 SUBJECT EFFECTIVE DATE September 9, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Opiate Dependence Treatments, Oral Buprenorphine Agents - Pharmacy
Assessment and Management of Opioid, Benzodiazepine, and Sedative-Hypnotic Withdrawal Roger Cicala, M. D. Assistant Medical Director Tennessee Physician s Wellness Program Step 1 Don t 1 It is legal in
Healthcare Committee Federal Response to Opioid Abuse Epidemic On May 1, 20215 the Energy and Commerce Subcommittee on Oversight and Investigations held a hearing entitled What is the Federal Government
Opioid Dependence Treatment with Buprenorphine/Naloxone: An Overview for Pharmacists and Physicians Phyllis A. Grauer, PharmD, CGP, CPE Clinical Pharmacist Legislation Passed Enabling Office Based Treatment
FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma Background A growing opiate abuse epidemic has highlighted the need for effective treatment options. This study documents
Heroin Overdose Trends and Treatment Options Neil A. Capretto, D.O., F.A.S.A.M. Medical Director Type date here www.gatewayrehab.org Drug Overdose Deaths Increasing in Allegheny County Roberta Lojak holds
Tufts Health Care Institute Program on Opioid Risk Management Pharmacotherapy for Prescription Opioid Addiction: Implications for Pain Management June 10 and 11, 2011 Executive Summary Introduction Opioid
Developing Medications to Treat Addiction: Implications for Policy and Practice Nora D. Volkow, M.D. Director National Institute on Drug Abuse Medications Currently Available For Nicotine Addiction Nicotine
Medication Assisted Treatment Tanya Hiser, MS, LPC State Opioid Treatment Authority Bureau Of Prevention, Treatment, & Recovery State of Wisconsin Elizabeth Collier, MSW, CSAC, ICS, LCSW TANF Best Practice
Narcotic Replacement Therapy Policy San Mateo County Alcohol and Other Drug Services Lea Goldstein, Ph.D. Brian Greenberg, Ph.D. The Narcotic Replacement Therapy (NRT) Policy Narcotic replacement programs
Low dose naltrexone secondary progressive ms Findings to date of these studies effects of naltrexone patients were randomized dosr receive either could overcome low dose naltrexone secondary progressive
John R. Kasich, Governor Orman Hall, Director 2 3 Epidemics of unintentional drug overdoses in Ohio, 1979-2011 1,2,3 1800 1600 1400 1200 1000 800 Prescription drugs are causing a larger overdose epidemic
Minimum Insurance Benefits for Patients with Opioid Use Disorder By David Kan, MD and Tauheed Zaman, MD Adopted by the California Society of Addiction Medicine Committee on Opioids and the California Society
Medications to address the opioid crisis - methadone, buprenorphine, naltrexone, and naloxone Alexander Y. Walley, MD, MSc Director, Addiction Medicine Fellowship and Addiction Medicine Consult Service
Medication-Assisted Treatment for Opiate Addiction and the Public Financing of that Treatment Introduction March 3, 2008 By: Suzanne Gelber, MSW, Ph.D., Managing Partner, The Avisa Group Defining Characteristics
Increasing Issues of Polypharmacy and Off-Label Drug Use in Psychiatric Care Stefan P. Kruszewski, MD Board Certified in Adult, Geriatric, Adolescent and Addiction Psychiatry, and Addiction Medicine Speaker
OBJECTIVES Learn about types of opioids and associated withdrawal symptoms Learn what medications are available to treat opioid addiction Understand the pros and cons associated with each medication Understand
We re glad you are here! Agenda for the Day Breaks Lunch Q&A and note cards Phones Learn about the history of opioid addiction and discuss what is happening today in Kentucky Learn about the disease of